Compare CFND & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | ECOR |
|---|---|---|
| Founded | N/A | 2005 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 39.6M |
| IPO Year | 2025 | 2018 |
| Metric | CFND | ECOR |
|---|---|---|
| Price | $4.98 | $7.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.50 |
| AVG Volume (30 Days) | N/A | ★ 75.1K |
| Earning Date | N/A | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | N/A | $41.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 27.90 |
| 52 Week Low | N/A | $4.16 |
| 52 Week High | N/A | $19.49 |
| Indicator | CFND | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 80.31 |
| Support Level | N/A | $5.57 |
| Resistance Level | N/A | $6.67 |
| Average True Range (ATR) | 0.00 | 0.49 |
| MACD | 0.00 | 0.26 |
| Stochastic Oscillator | 0.00 | 96.17 |
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.